New strategy aims to extend control of advanced colon cancer
NCT ID NCT04587128
Summary
This study is testing whether using anti-EGFR drugs like panitumumab or cetuximab earlier in treatment can better control metastatic colorectal cancer and allow patients to be retreated with these drugs later. It will enroll 71 adults with left-sided, metastatic colon cancer that cannot be surgically removed. The goal is to see if this approach helps keep the cancer from growing for longer periods and improves survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.